BusinessActinium Pharmaceuticals to Present at BIO Investor ForumBy Nasdaq OMXOct 16, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid LeukemiaBy Nasdaq OMXOct 4, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual MeetingBy Nasdaq OMXSep 13, 2017, 11:30 AM UTC
BusinessActinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common StockBy Nasdaq OMXJul 28, 2017, 1:10 PM UTC
BusinessActinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ETBy Nasdaq OMXJul 13, 2017, 11:00 AM UTC
BusinessActinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ETBy Nasdaq OMXJul 6, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing TeamsBy Nasdaq OMXJun 15, 2017, 11:00 AM UTC
BusinessActinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha TherapyBy Nasdaq OMXMay 23, 2017, 11:32 AM UTC
